All International Vaccine Institute articles
-
NewsImproved oral cholera vaccine achieves WHO PQ
EuBiologics and the International Vaccine Institute (IVI) announced that Euvichol-S, an improved oral cholera vaccine (OCV) developed jointly by EuBiologics and IVI, has achieved World Health Organization prequalification.
-
NewsAddressing both flu and COVID-19 through a single, multitasking injection
A study found a protein triggered the influx of acquired T cells and the proliferation of innate-like T cells in the lungs, which mounted a swift and comprehensive defense against a broad spectrum of pathogens.
-
NewsIVI starts technology transfer to Biological E. Limited to manufacture oral cholera vaccine for India and global markets
The International Vaccine Institute (IVI) has announced that it has commenced a technology transfer of simplified Oral Cholera Vaccine (OCV-S) to Biological E. Limited (BE), a leading India-based vaccines and pharmaceutical company.
-
NewsStudy indicates need for typhoid conjugate vaccines in endemic countries
A new study calls for stronger prevention strategies, including the use and implementation of typhoid conjugate vaccines (TCVs) in endemic settings along with improvements in access to safe water, sanitation, and hygiene.
-
NewsIVI to open Africa Regional Office in Rwanda
The International Vaccine Institute (IVI), an international organization with a mission to discover, develop, and deliver safe, effective, and affordable vaccines for global health, and the Ministry of Health of Rwanda have announced that IVI will open its Africa Regional Office in Kigali this year. The IVI ...
-
NewsSK bioscience’s typhoid conjugate vaccine achieves WHO prequalification
SK bioscience and the International Vaccine Institute (IVI) announced that the typhoid conjugate vaccine developed by SK bioscience with technology transfer from IVI has achieved the World Health Organization prequalification (PQ).
-
NewsSimplified formulation of oral cholera vaccine, licensed by Korean regulatory agency
Euvichol-S, a simplified formulation of oral cholera vaccine, has been licensed by Korean regulatory agency, and is expected to alleviate global cholera vaccine shortages.
-
NewsNew institute to bolster global preparedness for future pandemics
The University of Hong Kong (HKU), the University of Cambridge (UCAM), and the International Vaccine Institute (IVI) have established the international headquarters of The Hong Kong Jockey Club Global Health Institute at HKU.
-
NewsNew typhoid conjugate vaccine Bio-TCV® approved in Indonesia
Bio Farma’s Bio-TCV® typhoid conjugate vaccine (TCV) has been licensed in Indonesia following marketing approval from Badan Pengawas Obat dan Makanan (BPOM), the national regulatory authority.
-
NewsClover’s vaccine candidate reduced household transmission of SARS-CoV-2
A collaboration between Clover Biopharmaceuticals Ltd and the International Vaccine Institute showed that a household contact was 84% less likely to get a SARS-CoV-2 infection when the infected household member had received SCB-2019 (CpG 1018/Alum) compared to placebos.
-
NewsBiovac signs deal with IVI to deliver oral cholera vaccine for African and global markets
South African based Bio-pharmaceutical company Biovac has concluded a ground-breaking licensing and technology transfer agreement with the International Vaccine Institute (IVI), a non-profit international organisation headquartered in South Korea, for the manufacture of an oral cholera vaccine (OCV).
